Orchid Pharma's Cephalexin approved by USFDA, EDQM

Chennai: Orchid Chemicals & Pharmaceuticals, the city-based bulk drug major, has announced that its product Cephalexin has been formally approved by the US Food and Drugs Administration (USFDA).

According to the company, the product has also been granted the Certificate of Suitability (CoS) by the European Directorate for the Quality of Medicines (EDQM).

“We are extremely happy about these developments. Both these milestones will definitely enable a stronger entry into the US and European markets. We hope to take more of our products through the USFDA approval this year, based on established manufacturing facilities as well as new facilities under commissioning,“ says Orchid managing director K Raghavendra Rao.